
An update on the current treatment controversies for stress urinary incontinence and pelvic organ prolapse

Miss Ivilina Pandeva Consultant Subspecialist Urogynaecologist Croydon University Hospital, UK







- Natural history progression of prolapse and incontinence
- 20% Lifetime risk of surgery
- High re-operation rates (up to 30%)



- Olsen AL et al. . Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence. Obstet
 Gynecol. 1997
- Wu JM et al.. Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol. 2014







Ivilina Pandeva

IUGA Symposium 30 June 2019




Skin

Masci

After Mesh Repair

Hernia Example

Hernia repair with knitted polypropylene mesh FC Usher 1963 Surg Gynecol Obstet



- 1987 Lichtenstein reports outcomes of 6000 hernia repairs
- Safety of mesh in hernias
- 1992 Mesh colpopexy (Timmons et al.)
- 1996 Vaginal mesh for recurrent prolapse (TM Julian et al)

- 1996 ProteGen sling approved
 (Boston Scientific) woven polyester sling
- 1998 J & J clearance for Gynecare TVT
- 1996-2008 Numerous FDA approved

transvaginal mesh kits (FDA's 510(k) process)



ProteGen Sling Recall Boston Scientific

Cases Handled Nationally



- FDA enforcement report higher than expected rates of vaginal erosion and dehiscence
- By 2003 BS settles more than 700 cases of ProteGen (undisclosed)



Cochrane Database of Systematic Reviews

Traditional suburethral sling operations for urinary incontinence in women

Cochrane Systematic Review - Intervention Version published: 20 July 2005 see what's new

Authors' conclusions

The data on sub urethral sling operations remain too few to address the effects of this type of surgical treatment. Few trials are reported by authors in a complete fashion and most information came from abstracts presented in annual meetings. The broader effects of suburethral slings could not be established since trials did not include appropriate outcome measures such as general health status, health economics, pad testing, third party analysis and time to return to normal activity level. Data obtained from thirteen trials did not provide reliable estimates because of their sizes, and heterogeneity of designs, populations studied, and types of comparisons made.

Reliable evidence on which to judge whether or not suburethral slings are better or worse than other surgical or conservative management is currently not available.

NICE GUIDANCE

2005

Stresses the need to inform women of the lack of long term outcomes data

NICE National Institute for Health and Care Excellence

Cochrane Database of Systematic Reviews

Surgical management of pelvic organ prolapse in women

Cochrane Systematic Review - Intervention Version published: 18 July 2007 see what's new

Adequately powered randomised controlled trials are urgently needed.

Maher C, Baessler K, Glazener CMA, Adams EJ, Hagen S. Surgical management of pelvic organ prolapse in women. Cochrane Database of Systematic Reviews 2007.



Free Access

Tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence: 5-year follow up

KL Ward 🐹, P Hilton, UK and Ireland TVT Trial Group

First published: 07 December 2007 | https://doi.org/10.1111/j.1471-0528.2007.01548.x | Cited by: 205

- 344 randomised
- 5 years outcomes
- 1.7 % mesh complications; 81% cure rates



Vaginal Mesh for Prolapse: A Randomized Controlled Trial

Iglesia, Cheryl B. MD; Sokol, Andrew I. MD; Sokol, Eric R. MD; Kudish, Bela I. MD; Gutman, Robert E. MD; Peterson, Joanna L. RN; Shott, Susan PhD

Obstetrics & Gynecology: August 2010 - Volume 116 - Issue 2 - p 293-303


CONCLUSION: At 3 months, there is a high vaginal mesh erosion rate (15.6%) with no difference in overall objective and subjective cure rates. This study questions the value of additive synthetic polypropylene mesh for vaginal prolapse repairs.


Prolapse data






- 2005 2008: The FDA receives over 1,000 reports of transvaginal mesh injuries
- 2008: FDA first vaginal mesh safety alert
- 2008 2010: The FDA continues to receive over 2,800 adverse event reports of vaginal mesh injuries.










Ivilina Pandeva

IUGA Symposium 30 June 2019

Complications

Urethral TOT mesh exposure





FDA Safety Communication:

...from Jan. 01, 2008 through Dec. 31, 2010, the FDA received 2,874 additional reports of complications associated with surgical mesh devices used to repair POP and SUI, with 1,503 reports associated with POP repairs and 1,371 associated with SUI repairs. Although it is common for adverse event reporting to increase following an FDA safety communication, we are concerned that the number of adverse event reports remains high.

The FDA is issuing this update to inform you that serious complications associated with surgical mesh for transvaginal repair of POP are **not rare**

From 2008 – 2010, the most frequent complications reported to the FDA for surgical mesh devices for POP repair include mesh erosion through the vagina (also called exposure, extrusion or protrusion), pain, infection, bleeding, pain during sexual intercourse (dyspareunia), organ perforation, and urinary problems. There were also reports of recurrent prolapse, neuro-muscular problems, vaginal scarring/shrinkage, and emotional problems. Many of these complications require additional intervention, including medical or surgical treatment and hospitalization.

FDA 2011 recommends implants for POP reclassification from moderate to high risk

Jury Awards \$26.7 Million to Four Women Injured by Boston Scientific Pelvic Mesh!



An Indiana jury hit Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon with a \$35 million verdict in a product liability lawsuit brought over its Prolift pelvic mesh.



Hundreds sue over agonising vaginal mesh implants



Jury hits Ethicon with \$3.25 mln verdict in mesh case



Jury awards \$35M in mesh implant case

Arran depts faster Identialy disignet, Bare Ran dettes of versionality distances of versionality distances Arrange lateration Arrange latera

The second stars of the se

in the second se

Pinnacle' Pelvic Floor Repair Kit Devices



'I told my husband he could sleep with someone else': Mother-of-two, 43, can no longer have sex and depends on a mobility scooter after being fitted with controversial vaginal mesh implant

Daily Hlail



Hundreds of women left with health in ruins after bladder mesh ops, so why is treatment still offered?

The Scottish Independent Review of the Use, Safety and Efficacy of Transvaginal Mesh Implants in the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse in Women: Interim Report



Friday, October 2, 2015

Executive Summary

- 1. Robust clinical governance must surround treatment, the decision to use mesh and the surgical approach used.
- 2. Evidence of involvement in multi-disciplinary team working, audit activity, reporting of adverse events
- 3. Informed consent is a fundamental principle underlying all healthcare
- 4. The lack of extended long term follow up and related outcome data, including information on quality of life and activities of daily living, should be addressed.
- 5. Good information is essential to good patient care.
- 6. Improving awareness of clinical teams of the possible symptoms of mesh complications together with good communication skills, (including good listening and empathy) is an essential part of good clinical care.
- 7. A review of the different sources of evidence led us to express concern in the use of the transobturator rather than the retropubic approach
- 8. Concern both for effectiveness and adverse events, at the use of transvaginal mesh in surgery for pelvic organ prolapse.

England

NHS ENGLAND MESH WORKING GROUP REPORT

includes evaluation of both the efficacy and the extent and causes of adverse incidents and complication rates associated with these types of surgery:

Evidence

THE LANCET

Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997–2016: a population-based cohort study Joanne R Morling, PhD⁺ - David A McAllister, MD⁺ - Wael Agur, MD - Colin M Fischbacher, FFPH

Prof Cathryn M A Glazener, PhD - Karen Guerrero, FRCOG - Leanne Hopkins, MSc - Dr Rachael Wood, PhD

- Higher complication and re-operation rate
- No vaginal mesh in primary pelvic floor repair
- <u>The results supported the use of mesh procedures for incontinence, although further research on</u> <u>longer term outcomes would be beneficial</u>

SCIENTIFIC REPORTS

Received: 2 June 2017 Accepted: 30 August 2017 Published online: 20 September 2017

Ivilina Pandeva

OPEN Complications following vaginal mesh procedures for stress urinary incontinence: an 8 year study of 92,246 women

Kim Keltie^{1,2}, Sohier Elneil³, Ashwani Monga⁴, Hannah Patrick⁵, John Powell^{5,6}, Bruce Campbell⁷ & Andrew J. Sims 1,2

- HES data between 2007-2015
- 5.9 % were readmitted at least once within 5 years for further mesh intervention
- 9.8 % complication rate within 5 years of the mesh procedure

The UK edition ~ **Guardian**

'Scandal' of vaginal mesh removal rates revealed by NHS records

Traumatic complications mean one in 15 women fitted with the most common type of mesh support will require surgery to extract it, figures suggest

• Vaginal mesh implants: 'I really thought I was dying'

Transvaginal mesh use should be suspended, health groups say

Alliance of six state and territory consumer bodies say full audit of complications is needed

Transvaginal mesh inquiry criticises Australia's medical device regulation

Failure to protect women receiving the mesh implants cast health professionals in 'very poor light', inquiry finds





Royal College of ⁶ Obstetricians & Gynaecologists

Update on the Independent Medicines and Medical Devices Safety Review:Written statement - HCWS841

Baroness Cumberlege has reported to the Department of Health and Social Care an early finding of her review relating to surgical mesh. Following a number of engagement meetings with patients she has concluded that there should be a pause without delay in the use of surgical mesh for stress urinary incontinence (SUI).

Mesh safety alert

Published: 10/07/2018

High vigilance restrictions on use of vaginal mesh


On 10 July 2018, NHS Improvement and NHS England wrote to all acute trusts advising of the immediate implementation of a high vigilance restriction period regarding vaginal mesh.

For the majority of patients, mesh surgery should not be performed during this period of high vigilance restriction.

For some patients, mesh procedures may be the only viable treatment option. This includes cases where clinicians judge there is clinical urgency to carry out the procedure and no suitable alternative exists, and/or where delay would risk harm to the patient. However, this treatment should only be used in carefully selected patients who understand the risks and have given fully informed consent.

Ivilina Pandeva

IUGA Symposium 30 June 2019



Urinary incontinence and pelvic organ prolapse in women: management

NICE guideline [NG123] Published date: April 2019

- > multidisciplinary teams
- > urodynamic testing in urinary incontinence
- > absorbent products for urinary incontinence
- > medicines for overactive bladder
- > botulinum toxin A for overactive bladder
- > surgical procedures for stress urinary incontinence.

- > assessment and management of pelvic organ prolapse
- > management of coexisting urinary incontinence and pelvic organ prolapse
- > assessment and management of complications associated with mesh surgery for urinary incontinence or pelvic organ prolapse.

Surgical management of stress urinary incontinence

- Colposuspension (Open or Laparoscopic)
- Autologous fascial sling
- Paraurethral bulking if above options not acceptable
- Retropubic sling permanent and may not be removed fully. TOT unless RPR contraindicated

Surgery for pelvic organ prolapse

- Vaginal hysterectomy
- Pelvic floor repair
- Sacrospinous fixation
- Mesh sacrocolpopexy (Laparoscopic or open)
- colpocleisis

Managing complications associated with mesh surgery

- Regional MDT
- Limited evidence on atrial and complete mesh removal
- Significant complications of mesh removal surgery
- Symptoms recurrence
- Mesh centres



- Mesh introduced to overcome the shortcomings of native tissue repairs
- Vaginal mesh remains suspended
- Knock on effect on abdominal mesh surgery

Lessons learnt?

- More and more women request mesh removal
- *Robust MDT process to manage these complex patients*



DEPARTMENT of JUSTICE

FOR IMMEDIATE RELEASE

Friday, May 24, 2019

Surgical Funding Facilitator and Physician Charged in Alleged Nationwide Scheme to Defraud Women in Connection with Transvaginal Mesh Litigation

A surgical funding facilitator and a licensed urogynecologist were charged in a six-count indictment unsealed today for their roles in an alleged scheme to defraud women across the United States in connection with surgeries to remove transvaginal mesh (TVM) implants related to mass tort litigation.

PRIMUM NON NOCERE



